Chimeric antigen receptor T-cell therapy in relapsed or refractory mantle cell lymphoma: A systematic review and meta-analysis

In a meta-analysis of 16 studies comprising 984 patients, researchers evaluated the safety and efficacy of CAR T-cell therapy for patients with relapsed or refractory mantle cell lymphoma. They concluded that CAR-T therapy showed promising efficacy with manageable adverse reactions in this patient population. The pooled estimate for overall response rate was 89%, the complete remission rate was 74%, 6-month progression-free survival (PFS) was 69%, and 12-month PFS was 53%. The 6- and 12-month overall survival rates were 80% and 69%, respectively. Grade 3 or higher cytokine release syndrome was observed in 8% of patients, and grade 3 or higher neurotoxicity was observed in 22% of patients.